AUS
NZ
UK
CA
USA
IND
Highlights
- BELLUS said on Monday, December 13, that two doses of its BLU-5937 have achieved statistical significance.
- The biopharmaceutical company could attract investors' attention as it is nearing approval from the regulatory authorities.
- BELLUS is working to provide treatment of refractory chronic cough as around 9 million people are affected in the US.
BELLUS Health Inc. (TSX:BLU), a Canadian biopharmaceutical company has announced that its Phase 2 study of chronic cough therapy results are positive and it could boost the company's chances of getting approval.
BELLUS said on Monday, December 13, that two doses of its BLU-5937 have achieved statistical significance on the primary endpoint.
The results were from a Phase 2 trial for the treatment of a chronic cough condition.
Based on the 24-hour cough frequency, the biopharmaceutical company achieved a 34 per cent placebo-adjusted reduction. This is the primary endpoint achievement, and the reduction was recorded on the 28th day.
Also Read: 3 Canadian COVID stocks to buy amid Omicron’s emergence
According to the company, both 50 mg and 200 mg doses were well-tolerated and very few taste-related adverse events were reported.
What's next for BELLUS Health (TSX:BLU)?
The biopharmaceutical company could attract investors' attention as it is nearing approval from the regulatory authorities. Notably, the chronic cough condition, known as refractory chronic cough (RCC) affects 18 million patients in the United States and Europe.
© 2021 Kalkine Media
After the announcement, the Nasdaq listed shares of BELLUS Health jumped 42 per cent during pre-market hours, and the stock is expected to open well at the start of the trading session on December 13.
BELLUS is also exploring the use of BLU-5937 on patients who have cough hypersensitivity.
Bottom line
In Q3 2021, BELLUS had cash and cash equivalents of US$ 58.4 million, compared to US$ 98.3 million as of December 31, 2020.
Meanwhile, the net loss increased to US$ 22.9 million in Q3 2021 compared to US$ 5.7 million in Q3 2020.
Also Read: Moderna (MRNA) surges amid Omicron fears: A COVID stock to buy?
